Marius Pharmaceuticals Welcomes John "Shrek" Mcphee as Kyzatrex® (TU) CIII Capsules Patient Ambassador

madman

Super Moderator
1745607905461.webp







RALEIGH, N.C., April 22, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, announces its partnership with John “Shrek” McPhee, widely recognized in tactical and fitness communities as the “Sheriff of Baghdad,” who joins KYZATREX® (testosterone undecanoate) CIII capsules as a patient ambassador. McPhee is known for his strong advocacy of testosterone health and his clear preference for non-invasive treatment options.

“This is a great solution, I hate injections. Period,” said McPhee. “Finding KYZATREX means I can be on TRT without sticking myself with a needle or more likely, not being on testosterone at all. It’s effective, easy, and doesn’t screw up my routine.”

McPhee, a veteran with extensive experience in active military combat and pistol training—having trained over 15,000 individuals on the use of firearms—is a familiar voice on platforms such as the Joe Rogan and Shawn Ryan podcasts. McPhee has also appeared on the Power Athlete podcast, where he introduces the treatment and how KYZATREX has helped to improve his overall health.

Marius Pharmaceuticals applauds individuals who raise awareness about testosterone deficiency, particularly among veterans who often face challenges related to low testosterone. Research indicates that testosterone deficiency is a prevalent concern within veteran communities, highlighting the need for effective and patient-friendly treatment solutions. By joining the KYZATREX ambassador program, McPhee is helping to bring more attention to these important health issues.

“Partnering with John ‘Shrek’ McPhee, reinforces our commitment to making testosterone therapy accessible and effective,” said Marius Pharmaceuticals CEO Shalin Shah, adding, “With KYZATREX’s innovative, non-invasive formulation, we’re breaking away from outdated injection-based therapies and offering a more patient-friendly solution.”

 
 
 

Online statistics

Members online
2
Guests online
109
Total visitors
111

Latest posts

Back
Top